Disc Medicine, Inc.
NASDAQIRON enters the final week of June with a provocative divergence: the stock is up 6.6% on the day and nearly 10% over the past month, yet the CEO and COO have been selling aggressively — and short interest remains among the most elevated in the biotech universe. The insider activity is the dominant story this week. Executive selling has been heavy and coordinated. CEO John Quisel…
Snapshot as of 27 Jul 2026
IRON enters the final week of June with a provocative divergence: the stock is up 6.6% on the day and nearly 10% over the past month, yet the CEO and COO have been selling aggressively — and short interest remains…
Disc Medicine reports tomorrow with short conviction at its highest point in recent weeks — and the options market quietly shifting in the same direction. The dominant positioning story remains short interest, which…
Disc Medicine heads into its June 18 earnings report with short sellers quietly adding exposure and the ORTEX short score at a fresh weekly high. Short interest is the dominant story here. Bears have rebuilt their…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IRON — free to start on ORTEX.
Sign up for free →Open IRON on ORTEX